SIRNAOMICS-B News

IRNAOMICS(2257.HK):A DIFFERENTIATED BIOTECH COMPANY IN RNAI THERAPEUTICS

招银国际Jan 12 19:21

CICC: Maintains Shengnuo Pharmaceutical-B (02257) “Outperforms the Industry” rating and lowers the target price to HK$72.1

Zhitong FinanceSep 1, 2023 09:46

Nomura Adjusts Sirnaomics' Price Target to HK$67.07 From HK$70.07, Keeps at Buy

MT NewswiresJun 20, 2023 21:02

Nomura Adjusts Sirnaomics' Price Target to HK$70.07 From HK$107.14, Keeps at Buy

MT NewswiresMar 30, 2023 17:58

Shengnuo Pharmaceutical-B (2257.HK): Core products show skin cancer treatment potential and continue to improve the layout of indications

平安證券Aug 31, 2022 00:00

Shengnuo Pharmaceutical-B (02257.HK): A clinical-stage biopharmaceutical company exploring RNA therapy

中金公司Aug 2, 2022 00:00

Shengnuo Pharmaceutical-B (2257.HK): Small Nucleic Acid Track Pioneers Differentiate the Field of Oncology and Fibrosis

平安證券Jun 12, 2022 00:00

Shengnuo Pharmaceutical-B (2257.HK): IPO Purchase Guide

國元國際Dec 20, 2021 00:00

IPO News: Shengnuo Pharmaceutical-B (2257.HK)

致富證券Dec 20, 2021 00:00